Skip to main content
. Author manuscript; available in PMC: 2019 Apr 21.
Published in final edited form as: Lancet. 2018 Feb 7;391(10130):1599–1607. doi: 10.1016/S0140-6736(18)30204-6

Table 2.

Proportion of non-travelling vs travelling participants with yaws in the post-MDA period according to genotypes

Genotypes of yaws strains No Amplification
(n=31)		 Total
(n=208)
JG8 (n=149) SE7 (n=11) TG8 (n=1) TD6 (n=11) TG6 (n=3) SD6 (n=1) JD8 (n=1)
Non-travelling resident* 125 (83·9%) 2 (18·2%) 0 (0·0%) 11 (100%) 3 (100%) 0 (0·0%) 1 (100%) 26 (83·9%) 168 (80·8%)
Travelling or in-migrated participant† 24 (16·1%) 9 (81·8%) 1 (100%) 0 (0·0%) 0 (0·0%) 1 (100%) 0 (0·0%) 5 (16·1%) 40 (19.2%)
*

All non-travelling residents either absent or present at Mass Drug Administration.

†

Travel history was assessed by self-reported travel out of Lihir Island to a yaws endemic area in the preceding 6 months, regardless of compliance to MDA.

History of in-migration was assessed by self-reported migration to Lihir Island in the preceding 6 months and verified by non-appearance at the previous year census, regardless of compliance to MDA.